Skip to main content
. 2023 Feb 28;11(2):e006113. doi: 10.1136/jitc-2022-006113

Figure 3.

Figure 3

Combination of anti-CD20 immunotherapy and inhibition of BCL2 with venetoclax results in lymphoma reduction and prolonged survival in vivo. (A) Overall survival of pBIC mice that were untreated (receiving DMSO as vehicle), or treated with venetoclax (two i.p. weekly administrations of 250 µg), anti-CD20 (i.p. administration of 200 µg once a week) or the combination therapy, during a treatment window of 8 weeks (ie, 8 cycles). (B) Comparative percentages of CD19+GFP+ tumor cells and CD19+GFP- normal B cells from pBIC lymphomas at half-time of the treatment duration (4 weeks as indicated in the scheme, n≥3). (C) Comparative spleen length of pBIC animals in response to the different treatment regimens, measured at half-time (4 weeks) of treatment duration. Reference for normal length of control YC spleens is marked with a horizontal line (mean) and gray fill (SD). Circle symbols represent individual animals. Log-rank (Mantel-Cox) tests and parametric t tests were used for statistical analysis: *p≤0.05, **p≤0.01, ***p≤0.001, ****p<0.0001. MS, median survival; TME, tumor microenvironment; ven, venetoclax.